NCT04712110 - A Study of TAK-019 in Healthy Japanese Adults (COVID-19) | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

February 12, 2021

Primary Completion Date

March 28, 2022

Study Completion Date

March 28, 2022

Conditions

Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Interventions

BIOLOGICAL

TAK-019

TAK-019 intramuscular injection

BIOLOGICAL

Placebo

Placebo intramuscular injection

Trial Locations (2)

Sumida Hospital, Sumida-ku

Nishi Kumamoto Hospital, Kumamoto